Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
VTCN1 encodes a protein belonging to the B7 costimulatory protein family. Additionally we are shipping VTCN1 Proteins (37) and VTCN1 Kits (23) and many more products for this protein.
Showing 10 out of 206 products:
Human Polyclonal VTCN1 Primary Antibody for EIA, WB - ABIN955537
Xue, Luan, Gu, Wu, Zhang, Yu, Zhu, Wang, Dong, Geng, Zhang: The negative co-signaling molecule b7-h4 is expressed by human bone marrow-derived mesenchymal stem cells and mediates its T-cell modulatory activity. in Stem cells and development 2010
Show all 4 references for ABIN955537
Human Polyclonal VTCN1 Primary Antibody for IHC, ELISA - ABIN1584048
Basta, Galazka, Mach, Jozwicki, Walentowicz, Wicherek: The immunohistochemical analysis of RCAS1, HLA-G, and B7H4-positive macrophages in partial and complete hydatidiform mole in both applied therapeutic surgery and surgery followed by chemotherapy. in American journal of reproductive immunology (New York, N.Y. : 1989) 2011
Show all 4 references for ABIN1584048
Human Polyclonal VTCN1 Primary Antibody for ELISA, WB - ABIN451629
Krambeck, Thompson, Dong, Lohse, Park, Kuntz, Leibovich, Blute, Cheville, Kwon: B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. in Proceedings of the National Academy of Sciences of the United States of America 2006
Human Polyclonal VTCN1 Primary Antibody for IHC, IHC (p) - ABIN4282807
Xu, Zhang, Zhang, Liu, Yin, Liu, Zhuo: Clinical relevance of expression of B7-H1 and B7-H4 in ovarian cancer. in Oncology letters 2016
Human Polyclonal VTCN1 Primary Antibody for FACS, IF (p) - ABIN671736
Maskey, Li, Hu, Xu, Peng, Yu, Cao, Chen, Li, Yang: Impact of neoadjuvant chemotherapy on lymphocytes and co-inhibitory B7-H4 molecule in gastric cancer: low B7-H4 expression associates with favorable prognosis. in Tumour biology 2014
Results highlight an importance of VTCN1 stabilization on cell surfaces for the restora (show APCS Antibodies)tion of altered balance of immune control during T1D.
Ablation of B7-H3 (show CD276 Antibodies) but Not B7-H4 Results in Highly Increased Tumor Burden in a Murine Model of Spontaneous Prostate Cancer
B7-H4 expression by nonhematopoietic cells in the tumor microenvironment promotes antitumor immunity.
that B7x can modulate kidney damage in autoimmune diseases including lupus nephritis and anti-glomerular basement membrane disease
B7-H4 can inhibit both antitumor T cells and protumor myeloid-derived suppressor cells (
The endogenous expression of B7-H4 in donor beta cells from transgenic mice prolongs islet allograft survival, confirming the negative role of B7-H4 in regulating alloreactive T-cell responses.
Local overexpression of B7x on pancreatic beta cells is sufficient to abolish CD8 (show CD8A Antibodies) T cell-induced diabetes.
B7-H4 expression may influence the outcome of T-cell tumor cell interactions. Tumor-associated macrophage induced membrane-bound B7-H4 on lung cancer cell represents a novel mechanism by which lung cancer cells evade immune recognition and destruction.
Overexpression of B7-H4 was shown in tumor infiltrated dendritic cells.
Tissue-specific expression of B7x protects from CD4 (show CD4 Antibodies) T cell-mediated autoimmunity.
Unstable cell surface antigens are not suitable as targets for ADCC, and we therefore performed an indirect ADCC-redirecting T-cell cytotoxicity assay to study B7-H4 using polyclonal anti-mouse IgG antibody-mediated linking.
Knockdown of B7-H4 increased CD8 (show CD8A Antibodies)+ T cell-mediated cytotoxicity in vitro.
study provided the first evidence that B7-H4 facilitated esophageal squamous cell carcinoma cell proliferation through promoting IL-6 (show IL6 Antibodies)/STAT3 (show STAT3 Antibodies) positive loopback pathway activation
B7H4 antigen is a negative prognostic marker for pancreatic cancer patients and also seems to express resistance of pancreatic cancer patients to chemotherapy with gemcitabine.
B7-H3 (show CD276 Antibodies) and B7-H4 are involved in esophageal squamous cell carcinoma (ESCC) progression and development and their coexpression could be valuable prognostic indicators.
study suggest that serum B7-H4 is an independent prognostic indicator for HCC (show FAM126A Antibodies) and may be a promising biomarker for early diagnosis as well as disease prognosis of HCC (show FAM126A Antibodies).
Data show that disrupted control of costimulation, evidenced by VTCN1 loss in both APCs (show APCS Antibodies) and pancreatic islets, ultimately results in altered balance of control of immune responses.
Studied VTCN1 gene polymorphisms in susceptibility to Breast Cancer.
Data indicate that the diagnostic efficiency of V-set domain containing T cell activation inhibitor 1 (sB7-H4) combined carcinoembryonic antigen (CEA (show CEACAM5 Antibodies)) was superior to either sB7-H4 or CEA (show CEACAM5 Antibodies).
In human amniotic fluid stem cells, the negative co-stimulatory molecule B7H4 regulates low immunogenicity, which can provide a modest inflammatory reaction microenvironment for wound repair.
This gene encodes a protein belonging to the B7 costimulatory protein family. Proteins in this family are present on the surface of antigen-presenting cells and interact with ligand bound to receptors on the surface of T cells. Studies have shown that high levels of the encoded protein has been correlated with tumor progression. A pseudogene of this gene is located on chromosome 20. Multiple transcript variants encoding different isoforms have been found for this gene.
V-set domain-containing T-cell activation inhibitor 1
, V-set domain containing T cell activation inhibitor 1
, V-set domain containing T-cell activation inhibitor 1
, immune costimulatory protein B7-H4
, t cell costimulatory molecule B7x
, B7 family member, H4
, B7 superfamily member 1
, T cell costimulatory molecule B7x
, T-cell costimulatory molecule B7x